James N Topper bought $153k of PHAT
director at Phathom Pharmaceuticals, Inc.. 48,203 shares at an average of $3.17, traded May 9, 2025, filed May 13, 2025.
Score components
- +15RoleDirector
- +11Trade size$153k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context84% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-012770, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 9, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +33,376 | $3.19 | $107k | 33,376 | May 13, 2025 |
| May 9, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +2,226 | $3.62 | $8,053 | 35,602 | May 13, 2025 |
| May 12, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +12,601 | $3.04 | $38k | 48,203 | May 13, 2025 |
Related signals
Other insiders at Phathom Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | Robert Charles Breedlove Principal Accounting Officer | $7,079 524 shares | -1% | |
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | Robert Charles Breedlove Principal Accounting Officer | $5,573 461 shares | -1% | |
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | Robert Charles Breedlove Principal Accounting Officer | $14k 1,692 shares | -3% | |
| 31Weak | PHATbuy Phathom Pharmaceuticals, Inc. | James N Topper director | $15k 3,780 shares | +7% | |
| 39Weak | Phathom Pharmaceuticals, Inc. | James N Topper director | $24k 7,420 shares | +15% | |
| 44Moderate | Phathom Pharmaceuticals, Inc. | Asit Parikh director | $25k 10,000 shares | +12% | |
| 22Weak | PHATsell Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $17k 3,678 shares | -4% | |
| 44Moderate | Phathom Pharmaceuticals, Inc. | Terrie Curran President and Chief Executive | $126k 19,109 shares | -5% | |
| 36Weak | Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $43k 6,583 shares | -7% | |
| 30Weak | Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $10k 1,291 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.